-
French court confirms Moroccan football star Hakimi will stand trial for rape
-
South Korean leader says told Trump sanctions on North are 'ineffective'
-
Deadly Philippines quake turns seabed into shore
-
Stocks rally falters, oil rises as US-Iran talks postponed
-
S. Korean leader says he told Trump sanctions on North are 'ineffective'
-
Indonesia to capture last-known wild Bornean rhino for IVF
-
No vaccine, conflict, mistrust: Ebola's return to DR Congo
-
USA, Australia eye World Cup knockout rounds, Brazil in action
-
AI museum brings sights, sounds and smells of the rainforest
-
Iran to lodge complaint with FIFA over World Cup restrictions
-
'Old dog' Slipper out of retirement for Wallabies' Nations Championship campaign
-
New Zealand minister defends fishers after two orcas killed in net
-
Mexico into World Cup last 32, Canada celebrate historic win
-
Seoul record leads most Asian markets higher, crude extends losses
-
Co-hosts Mexico first team into World Cup knockout rounds
-
Burnham wins key UK poll, paving way for bid to challenge PM Starmer
-
Erasmus under 'no illusions' as tough Springboks season kicks off
-
'Pico' Lopes -- Cape Verde defender's journey from Ireland to World Cup
-
100 Colombian guerrillas disarm in deal with leftist government
-
'Pretty special': captains eye Super Rugby glory in clash of top seeds
-
Football 'ambassador' and fan favorite: a duck becomes a star in Mexico
-
Ivory Coast's Diomande living World Cup dream, dealing with tragedy
-
Slipper out of retirement for Wallabies' Nations Championship campaign
-
Australia seek 'respect' from US amid World Cup 'layup' row
-
New Zealand's Payne joins Paraguayan powerhouse after Instagram fame
-
Japan doctor-turned-author moots amputations to ease care crunch
-
Clark seizes four-stroke lead at darkness-halted US Open
-
Fossils challenge assumptions on how animals adapted to land
-
From private enterprise to property: Cuba's reforms unpacked
-
Canada romp to first World Cup win, Switzerland thump Bosnia
-
'Last ride': US says goodbye to Air Force One as Qatari jet awaits
-
Venezuela govt, opposition hold US-backed talks on democratic transition
-
Gabriel tells Brazil to turn the page against Haiti at World Cup
-
Horror injury overshadows Canada's first World Cup win
-
Cuba adopts historic package of free-market reforms
-
Swiss wunderkind Manzambi scores 'childhood dream' brace
-
US faces tough path to new Iran nuclear deal
-
Good US Open shots not good enough for 2-over Scheffler
-
Cuba unveils historic package of free-market reforms
-
Subs send Swiss to World Cup rout of Bosnia-Herzegovina
-
Stokes set for England return in New Zealand finale - reports
-
McIlroy pleased with reduced green speeds in US Open winds
-
Quarantine over for almost all hantavirus ship passengers, crew
-
US stocks resume upward climb as dollar advances again after Fed outlook
-
Ex-presidents and stars, but no Trump, turn out for Obama Library
-
Stevens seizes US Open lead with McIlroy, Aberg one back
-
Al-Qaeda-linked jihadists attack Niger airport, 11 soldiers killed
-
'Big-game' Bellingham shows his worth for England at World Cup
-
New Zealand's Henry rocks England in 2nd Test after Phillips century
-
Vance warns Israel against criticizing US-Iran deal
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB